JP2015514421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514421A5 JP2015514421A5 JP2015507006A JP2015507006A JP2015514421A5 JP 2015514421 A5 JP2015514421 A5 JP 2015514421A5 JP 2015507006 A JP2015507006 A JP 2015507006A JP 2015507006 A JP2015507006 A JP 2015507006A JP 2015514421 A5 JP2015514421 A5 JP 2015514421A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- seq
- chain
- class
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625314P | 2012-04-17 | 2012-04-17 | |
| US61/625,314 | 2012-04-17 | ||
| PCT/US2013/032058 WO2013158292A1 (en) | 2012-04-17 | 2013-03-15 | Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019019289A Division JP7130571B2 (ja) | 2012-04-17 | 2019-02-06 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015514421A JP2015514421A (ja) | 2015-05-21 |
| JP2015514421A5 true JP2015514421A5 (enExample) | 2016-05-12 |
Family
ID=48045753
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507006A Pending JP2015514421A (ja) | 2012-04-17 | 2013-03-15 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2019019289A Active JP7130571B2 (ja) | 2012-04-17 | 2019-02-06 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2022132891A Active JP7531925B2 (ja) | 2012-04-17 | 2022-08-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2024118377A Pending JP2024144548A (ja) | 2012-04-17 | 2024-07-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019019289A Active JP7130571B2 (ja) | 2012-04-17 | 2019-02-06 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2022132891A Active JP7531925B2 (ja) | 2012-04-17 | 2022-08-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2024118377A Pending JP2024144548A (ja) | 2012-04-17 | 2024-07-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20150056225A1 (enExample) |
| EP (2) | EP2838548B1 (enExample) |
| JP (4) | JP2015514421A (enExample) |
| AU (1) | AU2013249820C1 (enExample) |
| CA (2) | CA3085032A1 (enExample) |
| DK (1) | DK2838548T5 (enExample) |
| ES (1) | ES2959382T3 (enExample) |
| FI (1) | FI2838548T3 (enExample) |
| HU (1) | HUE063231T2 (enExample) |
| PL (1) | PL2838548T3 (enExample) |
| PT (1) | PT2838548T (enExample) |
| WO (1) | WO2013158292A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX373460B (es) * | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| KR20170075013A (ko) * | 2014-10-31 | 2017-06-30 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Cart 세포에서 유전자 발현의 변경 및 그의 용도 |
| EP3215623A4 (en) * | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| EP3229586B1 (en) | 2014-12-10 | 2025-07-30 | Regents of the University of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| WO2016112779A1 (en) * | 2015-01-17 | 2016-07-21 | Zhejiang University | Modified cells evoking reduced immunogenic responses |
| WO2016123100A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CA2988854A1 (en) * | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
| WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| EP4378957A3 (en) | 2015-07-29 | 2024-08-07 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| CN108368520B (zh) | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| WO2017078807A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| HK1257518A1 (zh) | 2016-01-11 | 2019-10-25 | Novartis Ag | 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白 |
| CA3022227A1 (en) * | 2016-04-27 | 2017-11-02 | University Health Network (Uhn) | Peptide-hla complexes and methods of producing same |
| KR20190103373A (ko) * | 2017-01-13 | 2019-09-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 면역조작된 만능 세포 |
| CN110637083A (zh) * | 2017-03-20 | 2019-12-31 | 华盛顿大学 | 细胞及其使用和制备方法 |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| US11312783B2 (en) | 2017-06-22 | 2022-04-26 | Novartis Ag | Antibody molecules to CD73 and uses thereof |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
| CA3067914A1 (en) | 2017-06-30 | 2019-01-03 | Cellectis | Cellular immunotherapy for repetitive administration |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| WO2019129850A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
| JP7372920B2 (ja) | 2017-12-29 | 2023-11-01 | セレクティス | Ｃａｒ ｔ細胞の作製を改良するための方法 |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN112955542A (zh) * | 2018-07-13 | 2021-06-11 | L·杰罗姆罗 | 非免疫原性工程化组织及其生产方法和用途 |
| US20210322473A1 (en) * | 2018-07-18 | 2021-10-21 | The General Hospital Corporation | Modified t cells and methods of their use |
| CN110819592A (zh) * | 2018-08-13 | 2020-02-21 | 赛元生物科技(杭州)有限公司 | 一种通用供体干细胞及其制备方法 |
| SG11202108346WA (en) | 2019-02-13 | 2021-08-30 | Beam Therapeutics Inc | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| CA3138597A1 (en) | 2019-05-10 | 2020-11-19 | The Regents Of The University Of California | Modified pluripotent cells |
| CN115279398B (zh) | 2019-09-27 | 2025-07-04 | 比姆医疗股份有限公司 | 治疗液态癌症的组合物和方法 |
| CA3170361A1 (en) * | 2020-02-07 | 2021-08-12 | Juntendo Educational Foundation | Cytotoxic t cells derived from human t cell-derived ips cells |
| WO2021231712A1 (en) * | 2020-05-15 | 2021-11-18 | Rxcell Inc. | Hypoimmunogenic cells and uses thereof in immune responses |
| WO2022038411A1 (en) | 2020-08-19 | 2022-02-24 | Astellas Pharma, Inc. | Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor |
| EP4200023A4 (en) | 2020-08-23 | 2024-10-30 | Applied StemCell, Inc. | Hla-f-modified cells and methods |
| CN114350612A (zh) * | 2020-09-28 | 2022-04-15 | 未来智人再生医学研究院(广州)有限公司 | 表达靶向CTLA-4的shRNA/shRNA-miR的多能干细胞或其衍生物 |
| CN114276995A (zh) * | 2020-09-28 | 2022-04-05 | 未来智人再生医学研究院(广州)有限公司 | 一种表达ctla-4阻遏分子的多能干细胞及其衍生物 |
| CN114457022A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用 |
| CN114517184A (zh) * | 2020-10-30 | 2022-05-20 | 未来智人再生医学研究院(广州)有限公司 | 一种表达adipsin的多能干细胞或其衍生物及应用 |
| CN114457021A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd47抗体的多能干细胞及其衍生物与应用 |
| CN114525254A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达fgf-21的多能干细胞或其衍生物及应用 |
| CN114457033A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-6阻断物的多能干细胞衍生物及其应用 |
| CN114525257A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Tim-3阻断物的多能干细胞或其衍生物及应用 |
| CN114457030A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达IgE阻断物的多能干细胞或其衍生物及应用 |
| CN114457024A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达IL-4Rα阻断物的多能干细胞或其衍生物及应用 |
| CN114457026A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达4-1bb激活型抗体的多能干细胞及其衍生物与应用 |
| CN114457028A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd38抗体的多能干细胞及其衍生物与应用 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| CN114645021A (zh) * | 2020-12-21 | 2022-06-21 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向cd47抑制因子的多能干细胞及其衍生物与应用 |
| CN114657131A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达尿酸氧化酶的多能干细胞或其衍生物 |
| CN114657130A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达vegf-a靶向抑制因子的多能干细胞及其衍生物与应用 |
| CN114657138A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向B7-H4的shRNA和/或shRNA-miR的多能干细胞或其衍生物 |
| CN114717192A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Amyloidβ靶向抑制因子的多能干细胞及其衍生物与应用 |
| CN114717193A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向B7-H5的shRNA和/或shRNA-miR的多能干细胞或其衍生物 |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| WO2022191216A1 (ja) | 2021-03-09 | 2022-09-15 | 国立研究開発法人理化学研究所 | 低免疫原性網膜色素上皮細胞の製造方法 |
| CA3216719A1 (en) | 2021-05-03 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Methods of generating mature corneal endothelial cells |
| TW202309268A (zh) | 2021-05-07 | 2023-03-01 | 安斯泰來再生醫藥協會 | 產生成熟肝細胞的方法 |
| AU2022299551A1 (en) * | 2021-06-23 | 2024-01-18 | Editas Medicine, Inc. | Engineered cells for therapy |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
| US20260002124A1 (en) | 2022-07-01 | 2026-01-01 | Novo Nordisk A/S | Enhancing neuronal differentiation of ventral midbrain neural progenitor cells |
| TW202417614A (zh) | 2022-08-23 | 2024-05-01 | 安斯泰來再生醫藥協會 | 用於治療眼部病症的感光救援細胞（prc）組成物及方法 |
| CN118207165B (zh) * | 2022-12-07 | 2026-03-20 | 士泽生物医药（苏州）有限公司 | 一种表达stc1的通用型细胞及其制备方法 |
| EP4735585A1 (en) | 2023-06-30 | 2026-05-06 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5574205A (en) * | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| WO1991010470A1 (en) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Devices and methods for enhanced delivery of active factors |
| WO1992009688A1 (en) * | 1990-11-21 | 1992-06-11 | Massachusetts Institute Of Technology | MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| EP0995798A1 (en) * | 1998-10-24 | 2000-04-26 | Novimmune Sa | Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances |
| US20040225112A1 (en) | 2003-05-06 | 2004-11-11 | Crew Mark D. | Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity |
| WO2007091078A2 (en) | 2006-02-10 | 2007-08-16 | Axordia Limited | Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g |
| US8105831B2 (en) | 2007-03-09 | 2012-01-31 | University Of Washington | Parvoviral production of HLA homozygous cells |
| CA3157027A1 (en) * | 2010-07-21 | 2012-01-26 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a t-cell receptor gene |
| JP2014513948A (ja) * | 2011-04-20 | 2014-06-19 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション | β２ミクログロブリン欠損細胞 |
-
2013
- 2013-03-15 PL PL13714128.9T patent/PL2838548T3/pl unknown
- 2013-03-15 CA CA3085032A patent/CA3085032A1/en active Pending
- 2013-03-15 DK DK13714128.9T patent/DK2838548T5/da active
- 2013-03-15 FI FIEP13714128.9T patent/FI2838548T3/fi active
- 2013-03-15 CA CA2870571A patent/CA2870571C/en active Active
- 2013-03-15 JP JP2015507006A patent/JP2015514421A/ja active Pending
- 2013-03-15 EP EP13714128.9A patent/EP2838548B1/en active Active
- 2013-03-15 EP EP23173587.9A patent/EP4253409A3/en active Pending
- 2013-03-15 HU HUE13714128A patent/HUE063231T2/hu unknown
- 2013-03-15 AU AU2013249820A patent/AU2013249820C1/en active Active
- 2013-03-15 US US14/391,328 patent/US20150056225A1/en not_active Abandoned
- 2013-03-15 PT PT137141289T patent/PT2838548T/pt unknown
- 2013-03-15 ES ES13714128T patent/ES2959382T3/es active Active
- 2013-03-15 WO PCT/US2013/032058 patent/WO2013158292A1/en not_active Ceased
-
2019
- 2019-02-06 JP JP2019019289A patent/JP7130571B2/ja active Active
- 2019-06-14 US US16/441,889 patent/US20190365876A1/en active Pending
-
2022
- 2022-08-24 JP JP2022132891A patent/JP7531925B2/ja active Active
-
2024
- 2024-07-24 JP JP2024118377A patent/JP2024144548A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heijmans et al. | Comparative genetics of the major histocompatibility complex in humans and nonhuman primates | |
| Behl et al. | The major histocompatibility complex in bovines: a review | |
| Grant et al. | The unconventional role of HLA-E: The road less traveled | |
| Norman et al. | Sequences of 95 human MHC haplotypes reveal extreme coding variation in genes other than highly polymorphic HLA class I and II | |
| Bontrop | Comparative genetics of MHC polymorphisms in different primate species: duplications and deletions | |
| Tomita et al. | BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis | |
| JP2022162047A5 (enExample) | ||
| Goldberg et al. | MHC structure and function–antigen presentation. Part 1 | |
| Augusto et al. | KIR and HLA under pressure: evidences of coevolution across worldwide populations | |
| McAdam et al. | Chimpanzee MHC class IA locus alleles are related to only one of the six families of human A locus alleles. | |
| JP2019507608A5 (enExample) | ||
| Price et al. | Heritable factors distinguish two types of alopecia areata | |
| Castelli et al. | HLA-E coding and 3′ untranslated region variability determined by next-generation sequencing in two West-African population samples | |
| Codner et al. | Constraints on haplotype structure and variable gene frequencies suggest a functional hierarchy within cattle MHC class I | |
| Bimber et al. | The killer‐cell immunoglobulin‐like receptors of macaques | |
| Ellis | The cattle major histocompatibility complex: is it unique? | |
| Baccala et al. | Mycoplasma arthritidis mitogen. Vβ engaged in mice, rats, and humans, and requirement of HLA‐DRα for presentation | |
| Augusto et al. | A deep look at KIR–HLA in Amerindians: comprehensive meta-analysis reveals limited diversity of KIR haplotypes | |
| de Groot et al. | Unraveling the architecture of major histocompatibility complex class II haplotypes in rhesus macaques | |
| Liu et al. | Major histocompatibility complex: Interaction with peptides | |
| Sakala et al. | Evidence for persistence of ectromelia virus in inbred mice, recrudescence following immunosuppression and transmission to naïve mice | |
| Schwartz et al. | The assembly and characterisation of two structurally distinct cattle MHC class I haplotypes point to the mechanisms driving diversity | |
| JP2025109839A5 (enExample) | ||
| JP2022553328A5 (enExample) | ||
| Watkins | MHC of nonhuman primates |